An oncologist examining a patient with advanced kidney imaging, using advanced AI diagnostics to predict kidney injury from chemotherapy treatment, with a medical monitor showing nephrotoxicity risk data. Hospital setting, cutting-edge medical technology in use.
Cisplatin, a chemotherapy drug, is widely used to treat various cancers. While effective, it comes with significant risks, including acute kidney injury (AKI). AKI can lead to severe complications or even long-term kidney damage. Now, a team of researchers has developed a new risk score to predict AKI, providing a vital tool for healthcare providers.
“Patients undergoing cisplatin treatment face a serious risk of kidney injury. Our goal was to develop a straightforward, accurate risk score to identify those at the highest risk,” explains Dr. Shruti Gupta, one of the lead researchers.
The research team focused on simplifying the risk prediction process. They aimed for a tool that could be easily integrated into clinical practice, benefiting both oncologists and nephrologists.
Development of the Risk Score
The study followed a cohort of cancer patients receiving cisplatin. The researchers collected extensive data, including demographic details, medical history, and cisplatin dosage. Through statistical analysis, they identified key predictors of severe AKI, such as age, body weight, and pre-existing kidney conditions.
“We needed a model that worked across diverse patient populations,” says Dr. Ilya Glezerman, another member of the team. “Our score combines multiple risk factors to give a reliable prediction.”
Once developed, the risk score was externally validated in a second group of patients. The results confirmed its accuracy, with healthcare providers able to identify high-risk patients early in the treatment process.
Implications for Clinical Practice
For oncologists, this tool could revolutionize how cisplatin chemotherapy is managed. Patients flagged as high risk can be monitored more closely, and preventive measures can be taken to reduce the likelihood of kidney damage.
“This score has the potential to significantly reduce AKI incidence in cisplatin-treated patients,” adds Dr. Jamie Hirsch. “By identifying those at risk, we can intervene earlier.”
Oncologists may also opt for alternative chemotherapy drugs or adjust the dosage of cisplatin based on the score, further minimizing risks.
Future Directions for Research
The research team hopes this model will inspire additional studies. “There’s more to learn about AKI in the context of chemotherapy,” remarks Dr. Wenxin Xu. The current risk score is designed specifically for cisplatin, but future models could expand to include other nephrotoxic cancer treatments.
The model is accessible and easy to implement. Researchers plan to collaborate with healthcare systems to make it a routine part of cancer care.
Citation:
Gupta S, Glezerman IG, Hirsch JS, et al. Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study. BMJ. 2023;384.
License:
This content is generated from the original article original article and it’s under Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
